Filing Flows › Lucid Diagnostics (LUCD) › Stock forecast & fair value
Lucid Diagnostics (LUCD) stock forecast and price target
Lucid Diagnostics (LUCD) trades at $0.40. 5 analysts' median price target is $3.00 (+654%), from $2.00 to $9.50.
Lucid Diagnostics' latest quarter
Lucid Diagnostics, Q2 2026: revenue $1.5M (+27% year over year), operating margin -868.5%, net loss $11.7M, operating cash flow −$11.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for LUCD stock?
The median of 5 analysts' 12-month targets is $3.00, +654% from $0.40; the range is $2.00 to $9.50. The average rating is strong buy.
Does Lucid Diagnostics usually beat earnings estimates?
It beat the consensus EPS estimate in 0% of the quarters on record.
Is LUCD stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.